Drugs / GVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03767582 | Dec 2019 → Feb 2025 | pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767582 ↗ |
| Modality | Vaccine | “Vaccine (5x10\^8 cells)” NCT03767582 ↗ |
| Route | Other | “Six intradermal injections every 4 weeks.” NCT03767582 ↗ |